Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran for Carotid Plaques in Atherosclerosis
NCT06586684Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
01
Overview
Phase 4, open-label, single-arm trial of inclisiran in atherosclerosis and Carotid artery disease (CAD), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoints: Carotid Intima-Media Thickness at 12 months, Total Maximum Plaque Thickness at 12 months and 3 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerosisCarotid artery disease (CAD)
Beyond the preview
Go deeper on NCT06586684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586684.